SBI Securities Co. Ltd. Buys Shares of 14,023 Achieve Life Sciences, Inc. (NASDAQ:ACHV)

SBI Securities Co. Ltd. purchased a new position in Achieve Life Sciences, Inc. (NASDAQ:ACHV) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 14,023 shares of the biopharmaceutical company’s stock, valued at approximately $49,000.

A number of other institutional investors also recently made changes to their positions in the stock. MetLife Investment Management LLC boosted its holdings in shares of Achieve Life Sciences by 65.6% during the third quarter. MetLife Investment Management LLC now owns 14,993 shares of the biopharmaceutical company’s stock worth $71,000 after purchasing an additional 5,939 shares during the last quarter. SG Americas Securities LLC lifted its position in Achieve Life Sciences by 74.8% during the fourth quarter. SG Americas Securities LLC now owns 19,886 shares of the biopharmaceutical company’s stock worth $70,000 after buying an additional 8,512 shares during the period. Sigma Planning Corp acquired a new stake in Achieve Life Sciences in the 4th quarter worth about $37,000. Verition Fund Management LLC purchased a new stake in Achieve Life Sciences in the 3rd quarter valued at about $113,000. Finally, State Street Corp grew its holdings in Achieve Life Sciences by 6.8% in the 3rd quarter. State Street Corp now owns 431,520 shares of the biopharmaceutical company’s stock valued at $2,045,000 after buying an additional 27,419 shares during the period. 33.52% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages recently commented on ACHV. Rodman & Renshaw began coverage on shares of Achieve Life Sciences in a research report on Thursday, November 14th. They set a “buy” rating and a $12.00 price target for the company. RODMAN&RENSHAW upgraded Achieve Life Sciences to a “strong-buy” rating in a report on Thursday, November 14th. Three research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $15.75.

Achieve Life Sciences Stock Down 2.5 %

Shares of NASDAQ:ACHV opened at $3.06 on Tuesday. The company’s fifty day moving average is $3.23 and its two-hundred day moving average is $4.06. The company has a debt-to-equity ratio of 0.31, a quick ratio of 6.78 and a current ratio of 6.78. Achieve Life Sciences, Inc. has a 1-year low of $2.82 and a 1-year high of $5.59. The stock has a market capitalization of $105.23 million, a price-to-earnings ratio of -2.71 and a beta of 1.67.

Achieve Life Sciences Profile

Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms.